R Squared’s Protara Therapeutics TARA Stock Holding History

R Squared’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30	Closed	-$158	–	1376
2024 Q4	$158	Buy	+30	New	+$97	﹤0.01%	1564

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

R Squared's TARA Position: Q1 2025 in Review

R Squared sold out of Protara Therapeutics (TARA) in Q1 2025, closing a stake of 30 shares — an estimated $158 sold.

R Squared first reported a position in TARA in Q4 2024 and held it in 1 quarter. The position peaked at $158 in Q4 2024. 59 funds tracked by Wall St. Rank hold TARA as of Q1 2025.

R Squared reported no remaining Protara Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 30 Protara Therapeutics shares in Q1 2025, an estimated $158.
R Squared first reported a position in Protara Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Protara Therapeutics position peaked at $158 in Q4 2024.
59 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.